Imiquimod

CHEMBL1282 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
240.3 g/mol
LogP
2.6
Phase
4

This topical immune response modifier is used to treat certain viral skin conditions including genital warts (condyloma acuminata), superficial basal cell carcinoma, and actinic keratoses. It works by stimulating the local immune system to produce interferon and other cytokines, which attack the abnormal or virus-infected cells. It is applied directly to the skin and should not be used internally.

분자량

240.3000 g/mol

LogP

2.60

TPSA

56.70 Ų

리핀스키 5의 법칙

통과

치료 영역

작용 기전

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)Cn1cnc2c(N)nc3ccccc3c21

InChI

InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)

Molecular Formula

C14H16N4

HBD / HBA

1 / 3

회전 가능 결합

2

무거운 원자

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This topical immune response modifier is used to treat certain viral skin conditions including genital warts (condyloma acuminata), superficial basal cell carcinoma, and actinic keratoses. It works by stimulating the local immune system to produce interferon and other cytokines, which attack the abnormal or virus-infected cells. It is applied directly to the skin and should not be used internally.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Imiquimod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1282. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 57469. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.